CN1290489C - Toad extract liposome preparation for injection and its preparing method - Google Patents
Toad extract liposome preparation for injection and its preparing method Download PDFInfo
- Publication number
- CN1290489C CN1290489C CNB2004100160647A CN200410016064A CN1290489C CN 1290489 C CN1290489 C CN 1290489C CN B2004100160647 A CNB2004100160647 A CN B2004100160647A CN 200410016064 A CN200410016064 A CN 200410016064A CN 1290489 C CN1290489 C CN 1290489C
- Authority
- CN
- China
- Prior art keywords
- extract
- bufo siccus
- preparation
- cholesterol
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a toad extract liposome preparation for injection and a preparation method thereof. The toad extract liposome preparation for injection contains toad extract of effective dose for treatment, phosphatidyl choline and cholesterol. Test data proves that the toxicity of the preparation of the present invention is obviously lower than that of the existing product, the treatment effect is good, the preparation has the target treatment effect, and the particle size distribution of the product of the present invention is uniform. The present invention can be used for treating various tumour diseases.
Description
Technical field
The present invention relates to a kind of pharmaceutical preparation that contains Bufo siccus extract, particularly contain the injection medicine preparation of Bufo siccus extract.
Background technology
Bufo siccus is the Amphibia anuran, and kind more than 250 is arranged, and it is very wide to distribute, and wherein a fairly large number of is Bufo siccus and Bufo melanostictus.The extract of its skin, glandular integumentaria and ear rear gland, sweet in the mouth, suffering, warm in nature.Toxin expelling, detumescence, heart tonifying, pain-relieving functions are arranged.Cure mainly malignant boil, diseases such as carbuncle, laryngopharynx swelling and pain.
Bufo siccus extract main component cardiotonic glycoside is the Venenum Bufonis poison, after its hydrolysis kind of bufotalin surplus 10.As: magnificent Toadpoison Medicine, magnificent bufotoxin, cinobufagin, hydroxyl cinobufagin, Toadpoison Medicine.Indole derivatives: bufotenine, the plain methine of toad, 5-hydroxy tryptamine, epinephrine etc.See (modern Chinese medicine pharmacology, Wang Benxiang chief editor, Tianjin science tech publishing house for details.1997, P1411).
Bufo siccus fat extract has certain clinical effectiveness to multiple cancer, especially to Lymphocytic leukemia (Jiang Kaixian chief editor, the clinical and research of Venenum Bufonis, TCM Document, Maritime Press, Beijing, 1994, P58).
The aqueous extract of Bufo siccus is to the neural collagenoma of the people of In vitro culture, hepatocarcinoma, cell such as leukemia and uterus carcinoma has inhibitory action (Zhang Yuyao, Xu Changzhao: the experimentation of the total composition of Venenum Bufonis water solublity, Nanjing Chinese medicine institute journal, 1998,7 (2): 33) (Yang Sujuan, the clinical practice of Bufo siccus and Venenum Bufonis and progress, Chinese medicine magazine, 1992,9 (5): 2).
The injection made from the Bufo siccus extract bufogenin is mainly used in respiratory stimulant at Japanese existing procucts, can increase the rich output of heart, adds high ventilating rate, and the effect of strengthening heart and boosting pressure is arranged.The domestic liquid drugs injection that Bufo siccus severe edema due to hypofunction of the spleen dissolubility extract is arranged, HUACHANSU ZHUSHEYE, Venenum Bufonis Injection, major function is a detoxicating, relieving inflammation, infect as acute, chronic purulent, antitumor, anticancer adjuvant drug has the general body state of improvement, recover cellular immune function, improve effects such as leukocyte level.The main effect of the oil of Bufo siccus, water extract is a heart tonifying, but also is main toxic action part.Because of its valid density is lower, limited its use.
Summary of the invention
The technical issues that need to address of the present invention are to disclose a kind of injection Bufo siccus extract Liposomal formulation and preparation method thereof, have circumscribed defective to overcome the use that prior art exists.
Technical conceive of the present invention is such:
Liposome can wrap up fat-soluble and two types of medicines of water solublity, and it is the direction-sense pharmaceutical carrier with multiple function.Liposome itself is little to human toxicity, and liposome do not have immunosuppressive action to human body, makes medicine have the targeting feature of directional profile in vivo.Medicine is encapsulated in liposome, can reduce drug toxicity.Because medicine is mainly absorbed by the phagocyte of reticuloendothelial system by after liposomal encapsulated, in the more rich organs of reticuloendothelial cell such as liver, spleen and bone marrow, concentrate, and the cumulant specific ionization medicine of medicine in heart and kidney is much lower.Therefore, as with those to heart, the virose medicine of kidney, especially to the virose antitumor drug of normal cell, be encapsulated as the toxicity that liposome can obviously reduce medicine.
For this reason, the inventor is through a large amount of tests, developmental research a kind of be the injection Bufo siccus extract Liposomal formulation of carrier with the liposome, to satisfy the needs of medical field.
Injection Bufo siccus extract Liposomal formulation of the present invention comprises Bufo siccus extract and the lecithin and the cholesterol for the treatment of effective dose, and wherein: the consumption between lecithin and the cholesterol is: 3～20 parts in lecithin, 0～10 part in cholesterol, weight portion;
Preferred ingredients and parts by weight comprise:
1 part in cholesterol
3～20 parts in lecithin
0.1～10 part of Bufo siccus extract
The effect of cholesterol is that the film-strength of liposome is increased, and to increase the stability of liposome, the effect of lecithin provides bilayer, contains medicine, and both are as the carrier of Liposomal formulation;
Said Bufo siccus extract comprises the Bufo siccus liposoluble extract or/and water solubility extract.
The liposoluble extract of being addressed refers to the effective ingredient that adopts water-insoluble organic solvent to extract from Bufo siccus, extracting method is existing play-by-play in numerous documents, and the present invention repeats no more.
The water solubility extract of being addressed is solvent with water, the effective ingredient that extracts from Bufo siccus is mainly indoles alkaloid and derivant thereof, existing detailed introduction in aforesaid document, extracting method is existing play-by-play in numerous documents, and the present invention repeats no more.Also can adopt the commercially available prod.
Toadpoison Medicine＜bfifalin is called for short BF), be one of the anti-midship tumor of liposoluble extract effect main component of Bufo siccus, can delay the life cycle of the growth rate and the prolong rats of rat implantation tumour.Toadpoison Medicine can optionally induce sick cell differentiation of human leukemia and accent to die, cell in vitro is cultivated proof, Toadpoison Medicine is the inducing leukemia natural death of cerebral cells when 10-7～10-5M, inducing leukemia cell differentiation then when 10-9～10-8M, and can recover the sensitivity of anti-clinically retinoic acid leukaemia to retinoic acid.Share with other antineoplastic agent, can improve the sensitivity of tumor cell antitumor drug.Although the above-mentioned mechanism of action of Toadpoison Medicine is still not fully aware of, may can to change the activity of mitogen-activated protein kinase in the cell (MAPK) relevant with Toadpoison Medicine, and then influence the expression of some oncogene.
Toadpoison Medicine is a hydrophobic drug, mouse peritoneal injection LD
50Be 2.2mg/kg, at present as yet not separately as medicinal application.
Said indoles alkaloid and derivant thereof are 30～63% (Sha Jingzhu to the suppression ratio of zoografting tumor, Mao Hongkui, HUACHANSU ZHUSHEYE, the pharmacy circular, 1987,22 (7): 438), be used for digestive system carcinomas such as hepatocarcinoma clinically, curative effect (Xuan Dianfa, Zhou Min preferably arranged, cinobufacin treatment primary hepatocarcinoma 69 routine short term effect preliminary observations, the combined therapy of Chinese and Western medicine, 1985,5 (2): 126), discovery cinobufacins such as Zhang Zhen is own have direct lethal effect to three kinds of digestive tract tumor, and effect and cisplatin are suitable.Site of action is at intracellular DNA, (Zhang Zhen oneself etc., cinobufacin is to three kinds of digestive tract tumor's cell killing Mechanism Study, Pharmacology and Clinics of Chinese Materia Medica, 1995,15 (5): experimentation.
According to the present invention, when being active component, being preferably in and adding 10～30 parts in dextran or mannitol in the above-mentioned composition again with the Bufo siccus water solubility extract, with support, form good preparation as dried frozen aquatic products.
The preparation method of above-mentioned injection Bufo siccus extract Liposomal formulation comprises the steps: when being active component with the Bufo siccus liposoluble extract
Get lecithin, cholesterol and Bufo siccus liposoluble extract such as Toadpoison Medicine are dissolved in organic solvent, and organic solvent is removed in decompression under 10～50 ℃ temperature again, adding water for injection handled in ultrasonic water bath 5～60 minutes, the high pressure homogenize is filtered, and adopts conventional method lyophilization to get final product.
The organic solvent of being addressed comprises chloroform or ethanol, preferred chloroform.
The preparation method of above-mentioned injection Bufo siccus extract Liposomal formulation comprises the steps: when being active component with the Bufo siccus water solubility extract
Lecithin, cholesterol with dissolve with ethanol after, dropwise splash into logical N
2The aqueous solution that is dissolved with Bufo siccus fat aqueous extract and dextran or mannitol that stirs rapidly, adopt conventional method lyophilization to get final product then.
When being active component as the while with Bufo siccus liposoluble extract and Bufo siccus water solubility extract, the preparation method of stating injection Bufo siccus extract Liposomal formulation comprises the steps:
(1) with cholesterol, lecithin and Bufo siccus liposoluble extract are dissolved in organic solvent such as the chloroform, heat in 10～50 ℃ of water-baths, remove chloroform and get the pastille immobilized artificial membrane;
(2) with lecithin, cholesterol with dissolve with ethanol after, dropwise splash into logical N
2The aqueous solution that is dissolved with Bufo siccus fat aqueous extract and dextran or mannitol that stirs rapidly;
(3) product with step (1) and step (2) adds in the entry, stirs down logical N
2Make dissolving, the high pressure homogenize is crossed 0.45u, behind the filter membrane of 0.2u, adopts conventional method lyophilizing to get final product.
Preparation of the present invention can be used for treating diseases such as hepatocarcinoma, pulmonary carcinoma, digestive tract tumor or leukemia, and general dosage＞3 μ g/kg body weight can be according to the state of an illness and patient decision, by intravenous injection.
Test data proves that preparation toxicity of the present invention is starkly lower than existing product, and therapeutic effect is good, and has the targeted therapy effect, and product cut size is evenly distributed.
Description of drawings
Fig. 1 is for being the liposome particle size distribution of active component with the Toadpoison Medicine.
The specific embodiment
Embodiment 1
Prescription:
Lecithin 5 grams, cholesterol 1 gram; Toadpoison Medicine 1 gram.
Preparation technology:
Get lecithin, cholesterol and Bufo siccus liposoluble extract such as Toadpoison Medicine are dissolved in the 18ml chloroform, and chloroform is removed in decompression under 40 ℃ temperature again, add water for injection 100ml, in ultrasonic water bath, handled 15 minutes the high pressure homogenize, filter, adopt conventional method lyophilization.
Its particle size distribution such as Fig. 1, the particle size distribution figure of Fig. 1 for recording with laser diffractometry, from scheming as seen, mean diameter is 80nm, does not see the particle greater than 200nm.
Prescription:
Lecithin 8 grams, cholesterol 1 gram, Bufo siccus water solubility extract 0.5 gram, Dextran 10 gram.
Preparation technology:
After lecithin, cholesterol are used the 15ml dissolve with ethanol, dropwise splash into logical N
2Stir rapidly be dissolved with Bufo siccus fat aqueous extract and dextran aqueous solution 200ml, use 5u, 0.45u, the membrane filtration of 0.2u adopts the method lyophilization of routine to get final product then.The particle size distribution that records with laser diffractometry is: mean diameter is 80nm, does not see the particle greater than 500nm.
Embodiment 3
Prescription:
(A) part: lecithin 9 grams, cholesterol 2 grams, Toadpoison Medicine 1 gram, bufogenin 0.5 gram, cinobufacin 0.14 gram.
(B) part: lecithin 5 grams, cholesterol 1 gram, Bufo siccus water solubility extract 0.5 gram, Dextran 10 gram or mannitol 20 grams.
Preparation technology:
(1) all material with (A) part is dissolved in the chloroform, reduces pressure in 40 ℃ of water-baths, removes chloroform and gets the pastille immobilized artificial membrane;
(2) with lecithin, cholesterol with dissolve with ethanol after, dropwise splash into logical N
2Stir rapidly be dissolved with Bufo siccus fat aqueous extract and dextran aqueous solution or Osmitrol;
(3) product with step (1) and step (2) adds in the entry, stirs down logical N
2Make dissolving, the high pressure homogenize is crossed 0.45u, behind the filter membrane of 0.2u, adopts conventional method lyophilizing to get final product.
The mean diameter that records with laser diffractometry is 70～80nm, and 99.5% particle is less than 200nm.
The acute toxicity of the bufalin liposome of embodiment 1:
The LD of free Toadpoison Medicine
50: 1.64 (1.5～1.8); The LD of embodiment 1
50: 3.68 (3.4～3.9)
The toxicity of bufalin liposome obviously descends, may be because they be many in the distribution of network structure endothelial system, and the heart place is few, and lymphsystem concentration height, main concentration reduces relevant.Therefore prompting may reduce its cardiac toxicity, and improves antitumor action.
Effect to anti-Mice Bearing Lewis Lung Cancer in the body of the bufalin liposome of embodiment 1 is tested, and the results are shown in following table:
| The administration group | Dosage mg/kg) | Mus number before and after the treatment is front/rear | The weight front/rear (g) of Mus before and after the treatment | Heavy X ± the SD (g) of tumor | Suppression ratio % |
| Normal saline | 0 | 10/10 | 19.2/22.7 | 2.76±0.35 | 0 |
| Bufalin liposome | 0.33 | 10/10 | 19.3/21.2 | 1.47±0.35 | 56.74 |
| 5-fluorouracil | 25 | 10/10 | 19.5/20.5 | 1.26±0.25 | 54.38 |
Embodiment 6
The acute toxicity of the preparation of embodiment 2:
The LD of Bufo siccus water extract
50: 1.3mg/kg; The LD of embodiment 2
50: 4.6mg/kg.
This shows that the liposome toxicity of embodiment 2 obviously descends, and helps antineoplaston.
Embodiment 7
The stability of formulation test of embodiment 3.
The compound formulation of embodiment 3 is placed 40 ℃, under the condition of 75%RH, situation of change behind the different time such as following table.
| Standing time | Particle size distribution | Toadpoison Medicine content (%) | Total indole alkali content (%) | |
| Mean diameter (nm) | Maximum particle diameter (nm) | |||
| 0 | 70 | Do not see greater than 500 | 100.0 | 100.0 |
| 1 | 80 | Do not see greater than 500 | 98.8 | 98.9 |
| 2 | 75 | Do not see greater than 500 | 99.0 | 97.9 |
| 3 | 75 | Do not see greater than 500 | 99.4 | 99.0 |
Stability test shows that the preparation of embodiment 3 is stable in 3 each months.
Claims (4)
1. injection Bufo siccus extract Liposomal formulation is characterized in that component and parts by weight comprise:
1 part in cholesterol
3～20 parts in lecithin
0.1～10 part of Bufo siccus extract
Said Bufo siccus extract is the Bufo siccus liposoluble extract.
2. preparation according to claim 1 is characterized in that, also comprises 10～30 parts in dextran or mannitol.
3. the preparation method of preparation according to claim 1 and 2 is characterized in that, comprises the steps:
Get lecithin, cholesterol and Bufo siccus extract are dissolved in organic solvent, and organic solvent is removed in decompression, and add water for injection and in ultrasonic water bath, handles minute, the high pressure homogenize, filtration, lyophilization gets final product;
Described organic solvent is selected from a kind of in chloroform or the ethanol.
4. the preparation method of preparation according to claim 2 is characterized in that, comprises the steps:
(1) with cholesterol, lecithin and Bufo siccus extract are dissolved in organic solvent, and organic solvent is removed in 10～50 ℃ of heating, get the pastille immobilized artificial membrane;
(2) with lecithin, cholesterol with dissolve with ethanol after, splash into logical N
2The aqueous solution that is dissolved with Bufo siccus fat aqueous extract and dextran or mannitol of stirring;
(3) product with step (1) and step (2) adds in the entry, stirs down logical N
2Make dissolving, the high pressure homogenize, behind the filter membrane, lyophilizing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100160647A CN1290489C (en) | 2004-01-29 | 2004-01-29 | Toad extract liposome preparation for injection and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100160647A CN1290489C (en) | 2004-01-29 | 2004-01-29 | Toad extract liposome preparation for injection and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1647799A CN1647799A (en) | 2005-08-03 |
| CN1290489C true CN1290489C (en) | 2006-12-20 |
Family
ID=34868193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100160647A Expired - Fee Related CN1290489C (en) | 2004-01-29 | 2004-01-29 | Toad extract liposome preparation for injection and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1290489C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1846712B (en) * | 2006-01-16 | 2012-01-11 | 西安安健药业有限公司 | Cinobufagin emulsion for injection and its preparation process |
| CN1985851B (en) * | 2006-08-07 | 2012-01-25 | 沈阳药大医药发展有限公司 | Lipoid microsphere injection containing toad cake extract and its preparing method |
| CN114432247A (en) * | 2022-01-18 | 2022-05-06 | 南京中医药大学 | Toad tryptamine liposome and preparation method and application thereof |
-
2004
- 2004-01-29 CN CNB2004100160647A patent/CN1290489C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1647799A (en) | 2005-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1810827A (en) | Anticancer prepn containing three anticancer compounds of toad or toad cake and its prepn process | |
| CN1951369A (en) | Coated nanoliposomes of resveratrol and preparation method thereof | |
| WO2015058664A1 (en) | Use of icariin in preparing medicine for preventing or treating decrease in blood cells | |
| JP6209579B2 (en) | Pharmaceutical composition that is regarded as a supplementary medicine | |
| CN105012271A (en) | Doxorubicin and TRAIL co-supported albumin nanoparticle targeting preparation and preparation method thereof | |
| CN1810241A (en) | Pharmaceutical use, medicine composition and prepn process of angelica oil components | |
| CN1290489C (en) | Toad extract liposome preparation for injection and its preparing method | |
| CN1281613C (en) | Chinese medicine gelsmium elegans total alkaloid for anticancer and analgesia, and medicinal composition containing it and preparing method thereof | |
| Mandal et al. | Strategic approach in hepatic delivery of andrographolide: Key challenges and new insights | |
| CN1718566A (en) | Ferulaic acid and its sodium salt used for preventing and treating senile dementia medicine | |
| CN1504191A (en) | Cucurbitacin lipsome preparation method and formulation | |
| CN1053376C (en) | Antineoplastic Chinese medicine prepn and its prepn process | |
| CN1278676C (en) | Curcumin injection and method for preparing the same | |
| CN1453295A (en) | Medicinal polysaccharide component of spinulate hedgehog fungus, its prepn and medicinal composition | |
| CN1762362A (en) | Medicinal composition with red sage root component for treating cardiovascular and cerebrovascular disease and its application | |
| CN1299667C (en) | Nano Chinese medicine threewingnut/Tripterygium prepn and its prepn process | |
| CN1839956A (en) | Pharmaceutical composition containing curcumin and its formulation | |
| CN104688722A (en) | Use of anhydroicaritin in preparation of myelosuppression prevention or treatment medicines | |
| US20060039999A1 (en) | Pharmaceutical composition for inhibition of tumor growth or metastasis | |
| CN113244208B (en) | Application of HPA in preparation of medicine for treating non-alcoholic fatty liver disease | |
| CN107550887B (en) | Compound nanometer preparation for treating T cell acute lymphoblastic leukemia, and preparation method and application thereof | |
| CN106344511B (en) | Nano liushen pill solution and its preparation method | |
| CN106265735A (en) | Functionalized multi-wall carbonnanotubes application in preparing medicine for anti transfer of tumor | |
| CN1286480C (en) | Oral disintegrants of composite salvia miltiorrhiza and their preparation | |
| CN1895346A (en) | Chinese-medicinal preparation for treating cardivascular and cerebrovascular diseases and its making method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061220 Termination date: 20190129 |